首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

2126419

神經退化性疾病生物標記市場：策略性洞察與預測（2026-2035）

Neurodegenerative Disease Biomarker Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計神經退化性疾病生物標記的市場規模將從 2026 年的 61.8 億美元成長到 2035 年的 176.7 億美元，複合年成長率為 12.4%。

受老齡化相關神經系統疾病盛行率不斷上升以及精準醫療需求日益成長的推動，全球神經退化性疾病生物標記市場正迅速擴張。該市場涵蓋臨床檢測、阿茲海默症診斷技術、影像生物標記以及用於檢測與進行進行性神經系統疾病（如阿茲海默症、帕金森氏症、多發性硬化症、肌萎縮側索硬化症 (ALS) 和亨廷頓舞蹈症）相關的生物指標的分析平台。生物標記能夠客觀地反映病理機制，例如澱粉樣蛋白沉積、 Tau蛋白聚集、神經軸突損傷、神經發炎、突觸功能障礙和基因突變。這種能力使臨床醫生能夠區分疾病亞型並更精準地監測進展。由於治療效果取決於對疾病病理生理機制和進展的準確識別，監管機構和醫療服務提供者日益認知到生物標記是精準醫療的關鍵工具。疾病修正治療的藥物創新越來越依賴基於生物標記的臨床試驗和伴隨診斷，以改善治療方案的選擇並監測治療反應。這些結構上的進步正在將生物標記確立為未來神經系統疾病診斷、藥物發現和針對每位患者量身定做的個人化醫療的基本要素。

市場促進因素

擴大血液衍生生物標記的應用

血液來源的生物標記在神經退化性疾病的診斷中發揮核心作用，它提供了一種微創的腦脊髓液 (CSF) 分析替代方案，同時有助於疾病的早期發現。隨著這些檢測方法能夠改善患者就診途徑並增強臨床擴充性，醫療專業人員正擴大將血漿生物標記（例如磷酸化Tau(p-tau)、神經絲輕鏈 (NfL)、乙型澱粉樣蛋白(AB) 和膠質纖維酸性蛋白 (GFAP)）納入其診斷流程。傳統的診斷方法通常需要侵入性操作或昂貴的影像學檢查，因此需要能夠簡化臨床評估的檢查室替代方法。診斷設備製造商正在擴展高靈敏度的免疫檢測技術，以在不同的醫療環境中提供標準化的分析效能。這種轉變正使血液來源的生物標記成為市場中最強勁的成長要素之一。

精準神經學的需求日益成長

精準神經病學依賴精確的分子表徵，因為神經退化性疾病儘管病理機制不同，但臨床症狀往往存在重疊。醫療專業人員擴大利用基於生物標記的診斷方法來改進疾病分類，並在不可逆的神經損傷發生之前最佳化治療決策。人們對傳統基於症狀的評估信心不足，這促使人們越來越需要客觀的生物學證據來區分疾病亞型。診斷開發公司正在建立整合蛋白質體學、基因組學和影像生物標記的綜合檢測平台，以增強臨床解讀。這種發展趨勢持續推動著神經健康整體先進生物標記技術的需求不斷成長。

疾病修正治療的擴展

隨著新型疾病修正治療的出現，治療合格越來越依賴對潛在疾病病理學觀察的確認，因此，經過檢驗的生物標記至關重要。製藥公司正在將生物標記終點納入臨床開發的各個階段，以最佳化患者篩選、監測治療反應並加速法規核准流程。醫療專業人員需要可靠的診斷測試，這些測試既能識別合適的治療候選者，又能同時支持疾病的長期監測。診斷公司正在透過開發可無縫整合到常規臨床實踐中的伴隨診斷平台來滿足這一需求。這些趨勢，加上治療領域的持續創新，正在進一步推動生物標記的應用。

生物標記分析的技術進步

蛋白質體學、基因組學、多重免疫檢測、質譜和人工智慧領域的持續創新正在提高生物標記的靈敏度和分析的可重複性。臨床檢查室擴大採用自動化平台，因為高通量技術能夠提高操作效率並降低分析變異性。隨著診斷變得日益複雜，對能夠在單一工作流程中同時評估多種生物標記的整合分析解決方案的需求也日益成長。技術供應商正在增強數位連接和基於雲端的分析能力，以支援整個醫療保健網路的標準化解讀。這些創新持續加速先進生物標記技術在整個神經系統疾病診斷領域的應用。

市場限制因素

嚴格的分析有效性要求和冗長的法規核准流程正在減緩新型生物標記檢測的商業化。新興生物標記檢測的保險覆蓋範圍有限，限制了其在某些醫療系統中的常規臨床應用。生物標記的標準化以及不同檢查室間分析表現的差異，都對廣泛的臨床應用構成挑戰。此外，先進分析平台的高成本也可能限制其在資源匱乏環境中的使用。

依生物標誌類型
- 蛋白質生物標記
- 基因生物標記
- 代謝生物標記
- 發炎生物標記
- 影像生物標記
- 其他生物標記
適應症
- 阿茲海默症
- 帕金森氏症
- 多發性硬化症
- 肌萎縮側索硬化症（ALS）
- 亨丁頓舞蹈症
- 其他神經退化性疾病
依檢體類型
- 血
- 腦脊髓液（CSF）
- 尿
- 唾液
- 組織
- 其他類型的檢體

第10章全球神經退化性疾病生物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球神經退化性疾病生物標記市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
產品發布和開發平臺進展

第13章：公司簡介

Roche Diagnostics
Fujirebio Holdings, Inc.
Quanterix Corporation
Bio-Techne Corporation
Abbott Laboratories
Siemens Healthineers AG
Beckman Coulter, Inc.
Sysmex Corporation
Thermo Fisher Scientific Inc.
Revvity, Inc.
C2N Diagnostics LLC
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings（Labcorp）
Becton, Dickinson and Company（BD）
Bio-Rad Laboratories, Inc.

第14章全球神經退化性疾病生物標記市場：商業預測分析

第15章投資與資金籌措分析

創業投資
政府與公共研究經費
產業研發投資

第16章：未來展望

新的成長機遇
長期產業趨勢

簡介目錄

Product Code: KSI-009130

The Neurodegenerative Disease Biomarker Market is anticipated to grow at a CAGR of 12.4% from USD 6.18 billion in 2026 to USD 17.67 billion in 2035.

The global neurodegenerative disease biomarker market is experiencing rapid expansion, driven by the increasing prevalence of age-associated neurological disorders and the growing demand for precision medicine. This market encompasses laboratory assays, molecular diagnostic technologies, imaging biomarkers, and analytical platforms that detect biological indicators associated with progressive neurological conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Huntington's disease. Biomarkers provide objective evidence of pathological mechanisms including amyloid deposition, tau aggregation, neuroaxonal injury, neuroinflammation, synaptic dysfunction, and genetic alterations. This capability enables clinicians to differentiate disease subtypes and monitor progression with greater precision. Regulatory authorities and healthcare organizations increasingly recognize biomarkers as essential tools for precision medicine because therapeutic effectiveness depends on accurate identification of disease pathology and progression. Pharmaceutical innovation in disease-modifying therapies is increasing reliance on biomarker-guided clinical trials and companion diagnostics to improve treatment selection and monitor therapeutic response. These structural developments position biomarkers as fundamental components of future neurological diagnosis, drug development, and personalized patient care.

Market Drivers

Growing Adoption of Blood-Based Biomarkers

Blood-based biomarkers are becoming central to neurodegenerative disease diagnosis because they provide minimally invasive alternatives to cerebrospinal fluid (CSF) analysis while supporting earlier disease detection. Healthcare providers are increasingly incorporating plasma biomarkers such as phosphorylated tau (p-tau), neurofilament light chain (NfL), amyloid-beta (AB), and glial fibrillary acidic protein (GFAP) into diagnostic workflows because these assays improve patient accessibility and clinical scalability. Conventional diagnostic methods often require invasive procedures or expensive imaging, creating demand for laboratory-based alternatives that simplify clinical evaluation. Diagnostic manufacturers are expanding highly sensitive immunoassay technologies capable of delivering standardized analytical performance across diverse healthcare settings. This transition establishes blood-based biomarkers as one of the strongest growth drivers within the market.

Increasing Demand for Precision Neurology

Precision neurology depends on accurate molecular characterization because neurodegenerative disorders frequently demonstrate overlapping clinical symptoms despite distinct pathological mechanisms. Healthcare providers are increasingly utilizing biomarker-guided diagnosis to improve disease classification and optimize therapeutic decision-making before irreversible neuronal damage progresses. Conventional symptom-based evaluation limits diagnostic confidence, creating demand for objective biological evidence that differentiates disease subtypes. Diagnostic developers are integrating proteomic, genomic, and imaging biomarkers into comprehensive testing platforms that strengthen clinical interpretation. This evolution continues expanding demand for advanced biomarker technologies across neurological healthcare.

Expansion of Disease-Modifying Therapies

Emerging disease-modifying therapies require validated biomarkers because treatment eligibility increasingly depends on confirmation of underlying disease pathology. Pharmaceutical companies are incorporating biomarker endpoints throughout clinical development to improve patient selection, monitor therapeutic response, and accelerate regulatory approval processes. Healthcare providers require reliable laboratory assays capable of identifying appropriate treatment candidates while supporting longitudinal disease monitoring. Diagnostic companies are responding through development of companion diagnostic platforms that integrate seamlessly into routine clinical practice. These developments reinforce biomarker adoption as therapeutic innovation continues advancing.

Technological Advancements in Biomarker Analysis

Continuous innovation in proteomics, genomics, multiplex immunoassays, mass spectrometry, and artificial intelligence is improving biomarker sensitivity and analytical reproducibility. Clinical laboratories are increasingly implementing automated platforms because high-throughput technologies enhance operational efficiency while reducing analytical variability. Growing diagnostic complexity creates demand for integrated analytical solutions capable of simultaneously evaluating multiple biomarkers within a single workflow. Technology providers are strengthening digital connectivity and cloud-based analytics that support standardized interpretation across healthcare networks. These innovations continue accelerating adoption of advanced biomarker technologies throughout neurological diagnostics.

Market Restraints

High analytical validation requirements and lengthy regulatory approval processes delay commercialization of novel biomarker assays. Limited reimbursement coverage for emerging biomarker tests restricts routine clinical adoption across several healthcare systems. Variability in biomarker standardization and inter-laboratory assay performance creates challenges for widespread clinical implementation. Additionally, the high cost of advanced analytical platforms can limit access in resource-constrained settings.

Technology and Segment Insights

By Biomarker Type

Protein biomarkers constitute the largest segment because they directly reflect pathological processes such as amyloid deposition, tau aggregation, neuroaxonal injury, and neuroinflammation. Healthcare providers are increasingly utilizing biomarkers including phosphorylated tau (p-tau217 and p-tau181), amyloid-beta (AB42/AB40), NfL, and GFAP to improve diagnostic confidence and monitor disease progression. Genetic biomarkers support identification of hereditary risk factors and inherited neurodegenerative syndromes. Metabolic biomarkers provide insights into cellular dysfunction and energy metabolism changes. Inflammatory biomarkers indicate neuroinflammatory processes associated with disease progression. Imaging biomarkers, including amyloid and tau PET tracers, offer complementary structural and functional information. Diagnostic companies are expanding highly sensitive immunoassays and multiplex protein detection platforms that improve analytical precision while supporting routine clinical implementation.

By Disease Indication

Alzheimer's disease represents the largest disease indication because increasing global prevalence is strengthening demand for accurate early diagnosis and treatment selection. Healthcare providers are increasingly adopting biomarkers such as amyloid-beta, phosphorylated tau, NfL, and GFAP because disease-modifying therapies require pathological confirmation before treatment initiation. Parkinson's disease is the second largest segment, driven by the need for biomarkers that differentiate it from other movement disorders. Multiple sclerosis, ALS, and Huntington's disease represent additional segments requiring specific biomarker solutions. The symptom overlap between various dementias and movement disorders creates diagnostic uncertainty, encouraging broader implementation of biomarker-guided clinical evaluation across all neurodegenerative conditions.

By Sample Type

Blood represents the fastest-growing sample type because minimally invasive collection improves patient acceptance, enables repeat testing, and supports large-scale screening initiatives. Healthcare providers are increasingly adopting plasma biomarker assays due to their compatibility with routine laboratory workflows and expanding clinical validation. CSF remains important for patients requiring high diagnostic certainty, particularly when blood-based results are inconclusive. Urine, saliva, and tissue samples represent emerging sample types with specific research applications. Diagnostic manufacturers are improving assay performance through advanced detection platforms and standardized analytical protocols. These developments are accelerating the transition toward blood-based precision diagnostics.

Competitive and Strategic Outlook

The competitive landscape features major diagnostic companies and specialized biotechnology firms. Roche Diagnostics differentiates itself through its integrated precision diagnostics ecosystem, combining advanced immunoassay technologies, automated laboratory platforms, and companion diagnostics. The company's Elecsys Amyloid Plasma Panel supports earlier Alzheimer's disease detection while reducing reliance on invasive CSF testing. Fujirebio Holdings specializes in neurological biomarkers with its Lumipulse automated immunoassay platform, including the FDA-cleared Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio assay. Quanterix Corporation is recognized for ultra-sensitive biomarker detection through its Simoa technology, enabling detection of neurological biomarkers at extremely low concentrations. Bio-Techne Corporation provides comprehensive protein analysis technologies, immunoassays, and reagents supporting biomarker discovery and translational research. Abbott Laboratories leverages its global diagnostics infrastructure to support adoption of neurological biomarker testing. Siemens Healthineers integrates laboratory diagnostics, neuroimaging, and digital health technologies into unified precision diagnostic ecosystems. Beckman Coulter provides high-throughput clinical laboratory automation and advanced immunoassay platforms. Sysmex Corporation combines clinical diagnostics, laboratory automation, and molecular technologies.
Strategic developments include increasing collaborations between diagnostic manufacturers and pharmaceutical companies to develop companion diagnostics aligned with emerging disease-modifying therapies. Companies are investing in multicenter clinical studies to validate blood-based biomarkers against CSF analysis and imaging. Mergers and acquisitions are enabling broader technological portfolios and geographic expansion. Product launches are focused on automated laboratory platforms, multiplex testing systems, and AI-enabled analytical software. Companies that successfully combine advanced biomarker discovery, automated laboratory technologies, and global clinical validation are expected to strengthen their competitive positions.

Conclusion

The neurodegenerative disease biomarker market is poised for exceptional growth, driven by the increasing prevalence of age-associated neurological disorders and the growing demand for precision medicine. The shift toward blood-based biomarkers, AI-enhanced analytics, and integrated diagnostic platforms is transforming clinical practice. Pharmaceutical innovation in disease-modifying therapies is creating sustained demand for validated biomarkers that support patient selection and treatment monitoring. Companies that successfully combine advanced biomarker discovery, automated laboratory technologies, and global clinical validation are expected to lead the market. Ongoing regulatory support, technological innovation, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Methodology
2.5 Assumptions & Limitations

3. Global Neurodegenerative Disease Biomarker Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Disease Overview
3.3 Biomarker Classification
3.4 Market Evolution
3.5 Key Market Trends
3.6 Historical Market Analysis (2021-2025)
3.7 Market Forecast (2026-2035)
3.8 Epidemiology and Disease Burden
3.9 Biomarker Development Landscape
3.10 Clinical Utility and Diagnostic Pathway
3.11 Unmet Clinical Needs

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Biomarker Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Artificial Intelligence in Biomarker Analysis
6.6 Digital Health Integration
6.7 Future Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Quality and Compliance Requirements

8. Global Neurodegenerative Disease Biomarker Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Disease Indication
8.3 Analysis by Sample Type
8.4 Analysis by Technology
8.5 Analysis by End User
8.6 Analysis by Application

9. Global Neurodegenerative Disease Biomarker Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 Protein Biomarkers
- 9.1.2 Genetic Biomarkers
- 9.1.3 Metabolic Biomarkers
- 9.1.4 Inflammatory Biomarkers
- 9.1.5 Imaging Biomarkers
- 9.1.6 Other Biomarkers
9.2 By Disease Indication
- 9.2.1 Alzheimer's Disease
- 9.2.2 Parkinson's Disease
- 9.2.3 Multiple Sclerosis
- 9.2.4 Amyotrophic Lateral Sclerosis (ALS)
- 9.2.5 Huntington's Disease
- 9.2.6 Other Neurodegenerative Disorders
9.3 By Sample Type
- 9.3.1 Blood
- 9.3.2 Cerebrospinal Fluid (CSF)
- 9.3.3 Urine
- 9.3.4 Saliva
- 9.3.5 Tissue
- 9.3.6 Other Sample Types